维生素D钙片联合骨化三醇治疗2型糖尿病性骨质疏松症的临床研究OA
Clinical trial of vitamin D calcium tablets combined with calcitriol in the treatment of type 2 diabetic osteoporosis
目的 观察维生素D钙片联合骨化三醇软胶囊治疗2型糖尿病性骨质疏松症的临床疗效和安全性.方法 用随机数表法把2型糖尿病性骨质疏松症患者分为对照组和试验组.对照组口服维生素D钙片,每次750 mg碳酸钙+2.5μg维生素D3,每天1次.试验组在对照组的基础上口服骨化三醇软胶囊,每次0.25 μg,每天1次.2组均持续治疗6个月.对比2组的糖代谢指标、骨密度(BMD)、骨代谢指标、血清学指标和临床疗效,并进行安全性评价.结果 研究共筛选247例,入组167例.试验组因未完成全程治疗脱落2例、自然失访脱落3例;对照组因未完成全程治疗脱落3例、自然失访脱落2例.最终对照组和试验组分别纳入78例和79例.治疗后,试验组和对照组空腹血糖(FPG)分别为(5.32±0.65)和(6.08±0.79)mmol·L-1,股骨颈 BMD 分别为(0.85±0.14)和(0.79±0.10)g·cm-2,骨特异性碱性磷酸酶(BALP)分别为(17.38±2.94)和(13.25±2.16)ng·mL-1,骨保护素(OPG)分别为(275.31±29.42)和(238.42±24.56)pg·mL-1,胰岛素样生长因子结合蛋白-3(IGFBP-3)分别为(4.37±0.72)和(3.19±0.45)μg·mL-1,胰岛素样生长因子-1(IGF-1)分别为(109.35±12.43)和(94.28±10.31)ng·mL-1,试验组的上述指标与对照组比较,在统计学上差异均有统计学意义(均P<0.05).治疗后,试验组和对照组总有效率分别为94.94%(75例/79例)和84.62%(66例/78例),在统计学上差异有统计学意义(P<0.05).试验组的药物不良反应有低热、腹胀和恶心呕吐,对照组有腹胀和恶心呕吐.试验组和对照组的药物不良反应总发生率分别为6.33%(5例/79例)和5.13%(4例/78例),在统计学上差异无统计学意义(P>0.05).结论 维生素D钙片联合骨化三醇软胶囊治疗2型糖尿病性骨质疏松症效果确切,可以改善糖代谢与骨代谢,增加BMD,促进血清IGFBP-3和IGF-1表达,且安全性可靠.
Objective To observe the clinical efficacy and safety of vitamin D and calcium tablets combined with calcitriol soft capsules in the treatment of type 2 diabetic osteoporosis.Methods Patients with type 2 diabetic osteoporosis were divided into control group and treatment group using a random number table.The control group received oral vitamin D and calcium tablets,each dose containing 750 mg of calcium carbonate and 2.5 μg of vitamin D3,administered once daily.The treatment group received oral calcitriol soft capsules at 0.25 μg per dose,once daily,in addition to the same treatment as the control group.Both groups continued treatment for 6 months.Glycometabolic indices,bone mineral density(BMD),bone metabolism indices,serological indices and clinical efficacy were compared between the two groups,and safety evaluation was conducted.Results A total of 247 cases were screened,and 167 cases were enrolled.In the treatment group,2 cases withdrew due to incomplete treatment and 3 were lost to follow-up;in the control group,3 cases withdrew due to incomplete treatment and 2 were lost to follow-up.Finally,78 and 79 cases were included in control and treatme groups,respectively.After treatment,the fasting plasma glucose(FPG)levels in treatment and control groups were(5.32±0.65)and(6.08±0.79)mmol·L-1,respectively;femoral neck BMD were(0.85±0.14)and(0.79±0.10)g·cm-2,respectively;bone-specific alkaline phosphatase(BALP)were(17.38±2.94)and(13.25±2.16)ng·mL-1,respectively;osteoprotegerin(OPG)were(275.31±29.42)and(238.42±24.56)pg·mL-1,respectively;insulin-like growth factor binding protein-3(IGFBP-3)were(4.37±0.72)and(3.19±0.45)μg·mL-1,respectively;and insulin-like growth factor-1(IGF-1)were(109.35±12.43)and(94.28±10.31)ng·mL-1,respectively.The differences in the above indices between treatment group and control group were all statistically significant(all P<0.05).The total effective rates in treatment and control groups were 94.94%(75 cases/79 cases)and 84.62%(66 cases/78 cases),respectively,with a statistically significant difference(P<0.05).The adverse drug reactions in treatment group included low-grade fever,abdominal distension,nausea and vomiting,while the control group experienced abdominal distension,nausea and vomiting.The total incidence of adverse drug reactions in treatment and control groups were 6.33%(5 cases/79 cases)and 5.13%(4 cases/78 cases),respectively,with no statistically significant difference(P>0.05).Conclusion Vitamin D and calcium tablets combined with calcitriol soft capsules are effective in the treatment of type 2 diabetic osteoporosis,improving glycometabolism and bone metabolism,increasing BMD,promoting the expression of serum IGFBP-3 and IGF-1,and demonstrate reliable safety.
王伟;张桂香;刘瑞瑞;吴文丽;尹彩君
宁夏回族自治区人民医院,内分泌科,宁夏银川 750000宁夏回族自治区人民医院,内分泌科,宁夏银川 750000宁夏回族自治区人民医院,内分泌科,宁夏银川 750000宁夏回族自治区人民医院,药学室,宁夏银川 750000宁夏回族自治区人民医院,核医学科,宁夏银川 750000
医药卫生
维生素D钙片骨化三醇软胶囊2型糖尿病骨质疏松症临床疗效
vitamin D and calcium tabletcalcitriol soft capsuletype 2 diabetes mellitusosteoporosisclinical efficacy
《中国临床药理学杂志》 2026 (6)
799-804,6
宁夏自然科学基金资助项目(2022AAC03381)
评论